within Pharmacolibrary.Drugs.ATC.A;

model A07DA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.004,
    Cl             = 0.0145,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0181,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010833333333333334,
    Tlag           = 9.96,            
    Vdp             = 0.0018,
    k12             = 61.2,
    k21             = 61.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07DA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Loperamide is a synthetic piperidine derivative and an opioid-receptor agonist that acts on the μ-opioid receptors in the large intestine. It is primarily used as an antidiarrheal agent to reduce the frequency of diarrhea. It is approved and widely used over-the-counter for the treatment of both acute and chronic diarrhea.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Loos, NHC, et al., &amp; Schinkel, AH (2024). Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment. <i>Cancer chemotherapy and pharmacology</i> 94(1) 79–87. DOI:<a href=\"https://doi.org/10.1007/s00280-024-04662-8\">10.1007/s00280-024-04662-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38456955/\">https://pubmed.ncbi.nlm.nih.gov/38456955</a></p></li><li><p>Matheson, AJ, &amp; Noble, S (2000). Racecadotril. <i>Drugs</i> 59(4) 829–837. DOI:<a href=\"https://doi.org/10.2165/00003495-200059040-00010\">10.2165/00003495-200059040-00010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10804038/\">https://pubmed.ncbi.nlm.nih.gov/10804038</a></p></li><li><p>Keyvanjah, K, et al., &amp; Wong, A (2019). Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. <i>Cancer chemotherapy and pharmacology</i> 84(5) 1125–1132. DOI:<a href=\"https://doi.org/10.1007/s00280-019-03951-x\">10.1007/s00280-019-03951-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31512028/\">https://pubmed.ncbi.nlm.nih.gov/31512028</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07DA03;
